5 Reasons Johnson & Johnson Is Having a Very Bad Month

Concerns over adverse reactions, blood clots, reports of breakthrough COVID cases in vaccinated people, vaccine contamination and scrutiny over CEO pay have plagued the roll-out of the company’s COVID vaccine.

It’s been a bumpy ride for Johnson & Johnson’s (J&J) COVID vaccine rollout.

Those weren’t the only negative headlines. Last week, J&J vaccine sites in four states had to shut down after reports of adverse reactions. There also were multiple reports of COVID breakthrough cases in people who received the vaccine, marketed under its subsidiary, Janssen.

J&J is on notice regarding investigations by European and U.S. regulators for reports of blood clots in individuals who received the vaccine.

And today, the company faced more backlash from investors after its CEO was awarded a 17% pay raise while billions are being paid out for the company’s role in the nation’s opioid epidemic.

Here’s a breakdown of the five reasons J&J is having a very bad month:

1. Vaccination sites shut down in four states after more than 45 people suffer adverse reactions.

A vaccination site in Colorado, three sites in North Carolina, one in Georgia and one in Iowa shut down last week after more than 45 people suffered adverse reactions to the J&J shot.

As The Defender reported April 8, more than 600 people with appointments were turned away from a J&J mass vaccination site in Colorado after several vaccine recipients suffered adverse reactions.

Centura Health, which helped run the community vaccination center at Dick’s Sporting Goods Park, said in a statement that 11 patients who received the vaccine experienced reactions. Two people were transferred to the hospital after medical staff determined they required additional observation. Centura officials did not specify what reactions were observed or their severity.

Health officials in Wake County, North Carolina, paused COVID vaccinations on Thursday after 18 people at the PNC Arena experienced adverse reactions and four were transferred to area hospitals. A few hours later, UNC Health’s Friday Center and Hillsborough Campus vaccination sites also stopped administering J&J’s vaccine.

The Centers for Disease Control and Prevention (CDC) analyzed the vaccine lot used at the PNC Arena and UNC sites and recommended J&J vaccinations continue.

Georgia was the third state to temporarily pause vaccinations after the Georgia Department of Public Health said eight people suffered adverse reactions at the Cumming Fairground site Wednesday. The CDC said it analyzed the vaccine lots and found no concerns.

The Pottawattamie County Health Department in Iowa paused operations April 7 after three of 35 people who received J&J’s COVID vaccine experienced adverse reactions. The site consulted with the CDC and determined the shot was safe.

Operations resumed on Thursday but the county now requires people to stay for 30 minutes instead of 15 minutes after their appointment to be monitored, KCCI News reported.

2. Reports of COVID in people fully vaccinated with J&J’s vaccine continue to mount.

A New Jersey man is in the hospital fighting for his life after being fully vaccinated against COVID, reported ABC7 NY. A woman reported she and her husband got J&J’s vaccine on March 6, but tested positive for COVID on April 1. The husband is hospitalized in critical condition and is also being treated for pneumonia.

According to the CDC, J&J’s vaccine was 66.3% effective in clinical trials, with people having the most protection two weeks after receiving the shot. Clinical trial data also indicated the vaccine was highly effective at preventing hospitalization in those who did get sick, according to the company.

Chief Health and Science Officer for the American Medical Association, Dr. Mira Irons, said on March 26 J&J’s COVID vaccine has “100% efficacy against hospitalization and death from the virus.”

Irons noted that White House Chief Medical Adviser Dr. Anthony Fauci, among other top experts said “it’s really important to focus on the severe end of the spectrum, preventing hospitalization and death.”

A Brooklyn woman, Ashley Allen, managed to avoid catching COVID during 2020, but was diagnosed with the disease three weeks after being vaccinated with J&J’s vaccine. Even after getting the one-shot vaccine, Allen said she continued to take precautions against the virus — masking up and washing her hands frequently.

“I definitely was very confused by it,” Allen said Monday, thinking perhaps it was a false positive.

As The Defender reported March 31, an increasing number of “breakthrough cases” of COVID in fully vaccinated people (including people vaccinated with Pfizer, Moderna and J&J vaccines) have been reported in Washington, Florida, South Carolina, Texas, New York, California and Minnesota. The cases included some people who required hospitalization, including at least three who died.

3. U.S. and European regulators are reviewing cases of blood clots in people who received J&J’s vaccine.

The U.S. Food and Drug Administration (FDA) is investigating rare blood clots in people who received the J&J vaccine, Fierce Pharma reported today.

The news came after Europe’s drug regulator said Friday it is reviewing reports of blood clots in people who received J&J’s COVID vaccine, Reuters reported.

The European Medicines Agency (EMA) said three serious cases of clotting and low platelets occurred in the U.S. during the rollout of J&J’s vaccine, and one person died from a clotting disorder reported during a clinical trial.

On April 7, the EMA confirmed a “possible link” between AstraZeneca’s COVID vaccine and blood clots. Like AstraZeneca, J&J uses a modified adenovirus vector as opposed to the mRNA technology used in the Moderna and Pfizer’s COVID vaccines.

J&J said it was aware of the reports of rare blood clots in individuals given its COVID vaccine and was working with regulators to assess the data and provide relevant information. The company also noted there was no causal relationship between these “rare events and the Janssen COVID-19 vaccine,” in a statement to Reuters.